Roche said a trial for its multiple-sclerosis drug Ocrevus failed to meet its primary endpoint in showing additional benefit in slowing disability progression with a higher dose. The Swiss ...

Swiss pharma giant Roche RHHBY faced a setback in its efforts to develop a higher dose of multiple sclerosis drug Ocrevus (ocrelizumab). The company announced that a phase III study, MUSETTE ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase III MUSETTE trial comparing a high dose of Ocrevus ® (ocrelizumab) intravenous (IV) infusion to ...